LightIntegra Technology, Inc.

About:

LightIntegra works to give patients requiring platelet transfusions the best care possible.

Website: http://www.lightintegra.com

Top Investors: WUTIF, Genome British Columbia, Boardwalk Ventures, Quimby Investments, Coleco Investments

Description:

LightIntegra Technology is a privately funded medical diagnostics company and launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer. LightIntegra strives to minimize platelet refractoriness. To this end, LightIntegra created ThromboLUX, a rapid in-vitro test that provides size distribution information for microparticles in blood products. As a routine test for platelet concentrates, ThromboLUX may identify which platelet units would be best suited for prophylaxis and which units are better suited for therapeutic use. Her years of research on platelet function led to a breakthrough discovery using dynamic light scattering to characterize platelets. Dr. Maurer recognized the opportunity to use this breakthrough - coupled with advances in laser and optics technology – to address a market need to provide a safe, quick and simple diagnostic test for microparticles, platelet quality and function.

Total Funding Amount:

$9.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Vancouver, British Columbia, Canada

Founded Date:

2009-01-01

Contact Email:

demo(AT)donotsend.com

Founders:

Bill Dubiel

Number of Employees:

11-50

Last Funding Date:

2020-06-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai